Assessment of Efficacy, Safety of mRNA COVID-19 Vaccines in Children Ages 5 to 11
EMBARGOED FOR RELEASE: 11:10 A.M. (ET), MONDAY, JANUARY 23, 2023
Media advisory: The full study and editorial are linked to this news release.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2022.6243?guestAccessKey=e77a8d4a-c5d4-415a-8a30-1b5d4478d31d&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=012323
About The Study: In this systematic review and meta-analysis including 17 studies with 10.9 million vaccinated and 2.6 million unvaccinated children ages 5 to 11, mRNA COVID-19 vaccination was associated with lower risks of SARS-CoV-2 infections, severe COVID-19–related illnesses, and hospitalizations due to COVID-19. While vaccination, compared with placebo, was associated with higher incidences of adverse events, the overall frequency of severe adverse events was low.
Authors: Jun Yasuhara, M.D., of Nationwide Children’s Hospital in Columbus, Ohio, and Toshiki Kuno, M.D., Ph.D., of the Albert Einstein College of Medicine in New York, are the corresponding authors.
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.